These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 31766149)
1. Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer. Maitra R; Thavornwatanayong T; Venkatesh MK; Chandy C; Vachss D; Augustine T; Guzik H; Koba W; Liu Q; Goel S Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766149 [TBL] [Abstract][Full Text] [Related]
2. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962 [TBL] [Abstract][Full Text] [Related]
3. Interplay between APC and ALDH1B1 in a newly developed mouse model of colorectal cancer. Golla JP; Kandyliari A; Tan WY; Chen Y; Orlicky DJ; Thompson DC; Shah YM; Vasiliou V Chem Biol Interact; 2020 Nov; 331():109274. PubMed ID: 33007288 [TBL] [Abstract][Full Text] [Related]
4. [Mouse models for human colorectal cancer with liver metastasis]. Huang XD; Zheng YB; Yang YJ; Yang C; Li HL; Cheng HR Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(34):2701-2705. PubMed ID: 31505723 [No Abstract] [Full Text] [Related]
5. Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. Zauber P; Marotta S; Sabbath-Solitare M BMC Cancer; 2016 Mar; 16():213. PubMed ID: 26970738 [TBL] [Abstract][Full Text] [Related]
6. Combined Mutation of Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223 [TBL] [Abstract][Full Text] [Related]
7. Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation. Miguchi M; Hinoi T; Shimomura M; Adachi T; Saito Y; Niitsu H; Kochi M; Sada H; Sotomaru Y; Ikenoue T; Shigeyasu K; Tanakaya K; Kitadai Y; Sentani K; Oue N; Yasui W; Ohdan H PLoS One; 2016; 11(11):e0166422. PubMed ID: 27835699 [TBL] [Abstract][Full Text] [Related]
8. EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. Srivatsa S; Paul MC; Cardone C; Holcmann M; Amberg N; Pathria P; Diamanti MA; Linder M; Timelthaler G; Dienes HP; Kenner L; Wrba F; Prager GW; Rose-John S; Eferl R; Liguori G; Botti G; Martinelli E; Greten FR; Ciardiello F; Sibilia M Gastroenterology; 2017 Jul; 153(1):178-190.e10. PubMed ID: 28400195 [TBL] [Abstract][Full Text] [Related]
9. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050 [TBL] [Abstract][Full Text] [Related]
10. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109 [TBL] [Abstract][Full Text] [Related]
11. Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. Saud SM; Li W; Morris NL; Matter MS; Colburn NH; Kim YS; Young MR Carcinogenesis; 2014 Dec; 35(12):2778-86. PubMed ID: 25280562 [TBL] [Abstract][Full Text] [Related]
12. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling. Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540 [TBL] [Abstract][Full Text] [Related]
13. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer. Wong CC; Wu JL; Ji F; Kang W; Bian X; Chen H; Chan LS; Luk STY; Tong S; Xu J; Zhou Q; Liu D; Su H; Gou H; Cheung AH; To KF; Cai Z; Shay JW; Yu J Nat Commun; 2022 Jul; 13(1):3971. PubMed ID: 35803966 [TBL] [Abstract][Full Text] [Related]
14. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Dow LE; O'Rourke KP; Simon J; Tschaharganeh DF; van Es JH; Clevers H; Lowe SW Cell; 2015 Jun; 161(7):1539-1552. PubMed ID: 26091037 [TBL] [Abstract][Full Text] [Related]
15. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825 [TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Asaka S; Arai Y; Nishimura Y; Yamaguchi K; Ishikubo T; Yatsuoka T; Tanaka Y; Akagi K Carcinogenesis; 2009 Mar; 30(3):494-9. PubMed ID: 19147861 [TBL] [Abstract][Full Text] [Related]
17. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations. Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123 [TBL] [Abstract][Full Text] [Related]
18. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports. Okada S; Hata K; Kawai K; Yamamoto Y; Tanaka T; Nishikawa T; Sasaki K; Kaneko M; Emoto S; Murono K; Nozawa H Medicine (Baltimore); 2019 Mar; 98(12):e14781. PubMed ID: 30896620 [TBL] [Abstract][Full Text] [Related]
19. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111 [TBL] [Abstract][Full Text] [Related]
20. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]